D&O Ongoing Disclosure – Malcolm Tubb

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
AFT Pharmaceuticals Limited (AFT)
Date this disclosure made:
14-Apr-21
Date of last disclosure:
24-Apr-20
Director or senior manager giving disclosure
Full name(s):
Malcolm Tubby
Name of listed issuer:
AFT Pharmaceuticals Limited (AFT)
Name of related body corporate (if applicable):
Not applicable
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
1. Unlisted options to acquire Fully-Paid Ordinary Shares in
AFT (Ordinary Shares)
2. Ordinary Shares in AFT
Nature of the affected relevant interest(s):
Registered holder and beneficial interest
For that relevant interest-
Number held in class before acquisition or disposal:
1. 50,000 unlisted options
2. 15,100 Ordinary Shares
Number held in class after acquisition or disposal:
1. 0 unlisted options
2. 65,100 ordinary shares
Current registered holder(s):
Malcolm Tubby
Registered holder(s) once transfers are registered:
Malcolm Tubby
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure-
Date of transaction:
13-Apr-21
Nature of transaction:
Exercise of 50,000 unlisted options and issue of 50,000
Ordinary Shares pursuant to AFT Share Option Plan
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or
disposal. If the consideration was not in cash and cannot be readily by converted into a cash value,
describe the consideration:Exercise price of NZ$2.80 per share / $140,000.00
Number of financial products to which the transaction related:
50,000
If the issuer has a financial products trading policy that prohibits directors or senior managers from
trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of during a closed period:Not applicable
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during
the closed period:
Not applicable
Date of the prior written clearance (if any):
Not applicable
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:Ordinary Shares
Nature of relevant interest:
1. Joint registered holder and beneficial owner as trustee of
the Jembag Trust
2. Power to control the exercise of the right to vote or
dispose of financial product
For that relevant interest,-
Number held in class:
1. 75,218
2. 3,574
Current registered holder(s):
1. Barbara Tubby, Colin Tubby & Malcolm Tubby as
trustees of the Jembag Trust
2. Barbara Tubby, Alison Tubby, Juliette Tubby, Emily
Tubby, George Tubby
For a derivative relevant interest,-
Type of derivative:Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if
any):
Not applicable
A statement as to whether the derivative is cash settled or physically settled:
Not applicable
Maturity date of the derivative (if any):
Not applicable
Expiry date of the derivative (if any):
Not applicable
The price's specified terms (if any):
Not applicable
Any other details needed to understand how the amount of the consideration payable under the
derivative or the value of the derivative is affected by the value of the underlying financial products:
Not applicable
For that derivative relevant interest,-
Parties to the derivative:
Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in
the derivative:
Not applicable

Certification
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is
correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:14-Apr-21